Dover

This research aims to understand how avacincaptad pegol, a treatment approved in the US, is used for people with geographic atrophy caused by age-related macular degeneration (AMD). Geographic atrophy is an advanced stage of AMD where cells in the retina waste away, leading to worsening central vision and possible permanent vision loss. The study focuses on observing treatment patterns and safety in routine clinical practice rather than testing new effects. Participants in this study will receive avacincaptad pegol through intravitreal injections, which are injections into the eye. The study collects information from patients who have already been prescribed this treatment by their doctors. There is no experimental intervention from the study team, and treatment decisions are made by the patients' doctors. The study follows patients for up to 3 to 5 years, depending on when they join. While in the study, participants will have regular eye exams as part of their usual care. They will also complete surveys about their eye health at the start of treatment, every 6 months for the first 2 years, then annually afterward. Researchers will track treatment details like the number and dose of injections, treatment duration, reasons for stopping treatment, and patient characteristics. Safety and treatment patterns are monitored through medical records during and after treatment.

Researchers are evaluating the safety of the IC-8 Apthera intraocular lens (IOL) after treatment for posterior capsular opacification (PCO), a common complication following IC-8 Apthera IOL implantation. This post-approval study is prospective, multi-center, and non-randomized, focusing on subjects who have previously received the IC-8 Apthera IOL and later developed PCO requiring Nd:YAG laser capsulotomy treatment. The study aims to monitor safety outcomes following this laser treatment using a standardized technique after sufficient surgeon training. Participants will receive the Nd:YAG laser capsulotomy treatment to address PCO in the eye with the IC-8 Apthera IOL. The study involves a single group of subjects, all having undergone prior IC-8 Apthera IOL implantation, with the other eye implanted with a monofocal or monofocal toric IOL. The study includes about six visits over a 24-month period following the IC-8 Apthera IOL implantation, during which safety and treatment outcomes will be assessed. During the study, subjects will be monitored for several outcomes including rates of additional Nd:YAG laser treatments, treatment complications, intraocular lens related assessments, secondary surgical interventions, serious adverse events, ocular adverse events, and subjective visual disturbances using specific questionnaires. Safety and effectiveness assessments will be conducted across the 24 months post-implantation, ensuring comprehensive evaluation of the IC-8 Apthera IOL after PCO treatment.